Recent

% | $
Quotes you view appear here for quick access.

Taseko Mines Ltd. Message Board

pfw2141 33 posts  |  Last Activity: Aug 26, 2015 4:18 PM Member since: Apr 9, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • When we will have some solid NEWS about MannKind future ???????????

    Today up $1.63,
    Pharma firm Novo Nordisk plans new plants for diabetes drugs in NC, Denmark by 2020

  • Reply to

    BUY BUY BUY

    by mako224117 Aug 21, 2015 4:58 PM
    pfw2141 pfw2141 Aug 22, 2015 6:30 AM Flag

    Think twice, September will be worst, TAX coming up and the whole World finance getting slaughterers

    Sentiment: Hold

  • Reply to

    down again today..

    by cory_mc69 Aug 18, 2015 2:47 PM
    pfw2141 pfw2141 Aug 19, 2015 6:08 PM Flag

    shame n you, you are to judge or to speak with so much liberty about people opinion?
    IMBECILE what not necessary, read your previous posting and learn , you mention $4.00 don't you??

  • Reply to

    Next Uptick And I'm Throwing In The Towel!!!!

    by golf.paul123 Aug 5, 2015 3:08 PM
    pfw2141 pfw2141 Aug 5, 2015 3:22 PM Flag

    I bought my 15K a 13.96 last March and sold it at 10.85 and bought EGRX and CARA, I have cover already my losses and made some gain, BUT I am ready to go back when the time will be right, with more buying power, some big names are involved and own a lot of KERX, the waiting game have only one name
    "PATIENCE" faites vos jeux .... rien ne va plus

    Sentiment: Hold

  • Reply to

    Was $98.08 Now $97 something..

    by dc7177 Jul 20, 2015 1:41 PM
    pfw2141 pfw2141 Jul 20, 2015 8:09 PM Flag

    You do not know nothing about trading, the Chart is telling you buy!
    This stock will be become the best stock EVER in our country. soon.
    S100.00, NO very much above,
    I have bought last year enough for the KIDS future at $53.99, and keep buying today,
    I DON'T KNOW BUT SOMETHING BIG COMING UP, AND I WANT TO BE THERE TO ENJOYED
    THE PAY OFF.

    Sentiment: Strong Buy

  • pfw2141 pfw2141 Jul 17, 2015 10:14 AM Flag

    westsidewineandspirits, please READ "sadiecc2 " REPLY, you may learn something, I was myself , please from this inteligente explanation, who WILL BE READ by many Peoples, Thank you sadiecc2,
    Mr westsidewineandspirits , will be going to visit the "Wizard oz " with Shrek to get a brain.

  • THE BEST SECRET IN TOWN,................. ADVERTIZE

    Shares of MannKind (NASDAQ:MNKD), a biopharmaceutical company focused on the development of therapies to treat diabetes, surged by 10% in June (per S&P Capital IQ) following positive analyst commentary and a likely short squeeze.

    In mid-May, Jefferies analyst Shaunak Deepak suggested that once MannKind and licensing partner Sanofi begin advertising for Afrezza, sales of MannKind's inhalable diabetes drug should improve. Additionally, Deepak said he believes a lack of understanding regarding Afrezza among primary care physicians, based on his own nonscientific surveys, has impaired the drug's launch.

    From nearly the moment Deepak issued his commentary through mid-June, MannKind's stock practically doubled. I suspect this was partly a function of Deepak's optimistic commentary, but also based on MannKind's high levels of short interest.

    Sentiment: Strong Buy

  • pfw2141 pfw2141 Jul 6, 2015 11:09 AM Flag

    In Germany shorting is VERBODEN, they have some of the largest Biotech Companies in the World.
    Don't know why??

  • pfw2141 pfw2141 Jul 6, 2015 10:53 AM Flag

    They are ! ,very strong liberal socialist , our UAW Dennis Williams President look like a red cross volunteer compare with prime M Tsipras, good friend of Putin.

  • Jul 6, 2015, 7:00am EDT
    BY Don Seiffert
    Boston Business Journal

    SIC BUT SO TRUE

    Say you woke up tomorrow morning and decided you’d like to make sure that women struggling to get pregnant would continue to struggle; that patients on kidney dialysis would never get a break from monthly blood transfusions; or that boys with Duchenne muscular dystrophy would continue to be forced to use a wheelchair by age 12. Probably one of the best first steps you could take to achieve that goal would be to become a short seller of healthcare stocks.

    Short sellers — investors who profit off of a decline in the stock price of a company — pose one of the biggest threats to small, publicly-traded companies developing life-saving drugs and devices. Those kinds of companies make up the vast majority of the 30-plus Massachusetts-based biotech firms that have held initial public offerings since 2013. They are typically small, and are putting all their efforts into one or two products with a promise to save lives in areas where there are currently few or no good treatments.

    Last week, I published an article about the most-shorted biotech firms in the Boston area. The top three on that list: Sarepta Therapeutics (Nasdaq: SRPT), OvaScience (Nasdaq: OVAS) and Keryx Biopharmaceuticals (Nasdaq: KERX). I’ve spoken personally with the CEOs and other executives of all three of those companies, but no one at any of those companies suggested I write this story.

    Sentiment: Strong Buy

  • Reply to

    What A MannKind Investor Needs To Know

    by pfw2141 Jul 2, 2015 11:24 AM
    pfw2141 pfw2141 Jul 2, 2015 3:04 PM Flag

    NEXT YEAR, SOMETIME .......................On my way to the Bank ........................
    Perhaps The Strongest "I Told You So"

    Sentiment: Strong Buy

  • Reply to

    What A MannKind Investor Needs To Know

    by pfw2141 Jul 2, 2015 11:24 AM
    pfw2141 pfw2141 Jul 2, 2015 11:30 AM Flag

    Any investor currently holding a position in the stock or planning to establish a position before the potential-blockbuster gets going must be open to more volatility in the stock. The price per share does not always behave the way news or progress may suggest. I have seen shorts beat the hell out of the stock on several occasions over the three year timeframe I have closely followed the biotech. MannKind has been the 5th most shorted stock on the NYSE. Currently, 120 million shares are held short, which represents more than an 8% decrease since May, when 131 million shares were held short. With so many short positions being reduced, the volatility of the stock is unclear. These shorts were not all wrong and their positions likely profited, but short interest is decreasing because they realize it is becoming time to buy. Shorts believed sales would be slow, which is what investors were told to expect by Sanofi/MannKind with the announcement of a soft launch. These shorts also believe they can make a killing because of MannKind's debt position. Yet, MannKind has milestone payments coming up, and $150 million of MannKind's "debt" is a prepayment by its partner, Sanofi. Their accounts payable have decreased significantly this year and currently hold over $120 million in cash. I also find confidence in the fact that almost 40% of the stock is owned by insiders, with less than 1 million shares sold by insiders over the past six months. Positive catalysts have the potential to force shorts to run for the hills in what is known as a "short-squeeze," which would drive the share price muchhigher.

  • Summary

    Afrezza prescriptions have increased week over week despite analysis insisting on calling the planned soft launch a "failed launch".
    Afrezza is still not Exubera.
    The Technosphere platform is the closest thing to disruptive technology the diabetes market has ever seen.
    Afrezza has a healthy buzz across social media with overwhelmingly positive testimonials, which is yet another form of DTC awareness.
    Insurance coverage is the greatest hurdle for Sanofi and MannKind in the short run, but providers, such as Humana will make their decision on Afrezza coverage in the near term.

    Afrezza is just the first drug to arrive on MannKind's (NASDAQ:MNKD) Technosphere platform. Afrezza is not Exubera.
    In fact, patients have praised the new inhalable insulin therapy since its February launch. Afrezza delivers relief instantly, in fewer milligrams, and with a much smaller Dreamboat device. The Technosphere platform can be described as a disruptive technology that the diabetes market hasn't seen for a while. Honestly, I could go on, but those are the top three in my opinion

    Sentiment: Strong Buy

  • MannKind investors were disappointed when its marketing partner Sanofi revealed that Afrezza generated only $1.1 million sales in the first two months of launch. On the other hand, RBC Capital Markets analyst Adnan Butt and Jefferies analyst Shaunak Deepak have reiterated that Afrezza sales are picking up, albeit slowly. The two research firms have been keeping close tabs on the prescription numbers of MannKind's inhaled insulin treatment.

    Sentiment: Buy

  • Reply to

    The 6 Most Heavily Shorted Nasdaq Stocks in June

    by pfw2141 Jun 26, 2015 10:31 AM
    pfw2141 pfw2141 Jun 26, 2015 10:32 AM Flag

    post twice maybe ..............

  • The Product is great for some, and the Management are on the right track, our BIG PROBLEMS, manipulation and short. One of the 6 most shorted
    MannKind Corp.’s (NASDAQ: MNKD) short interest, at more than 120.42 million shares as of June 15, was down 8.2% from the previous period. Note that it was 47% of the total float, as well as the second highest short interest in at least a year. The days to cover dropped from more than 12 to about eight. In early June, it looked like MannKind had become a tug-o-war stock. Shares ended Wednesday at $5.85, in a 52-week range of $3.46 to $11.48. The stock saw a share price increase of more than 40% in early June, though it gave up much of that gain by the end of the two-week short-interest period.

    Sentiment: Buy

  • Product is great, but manipulation is terrible, nothing to do with Management team............

    MannKind Corp.’s (NASDAQ: MNKD) short interest, at more than 120.42 million shares as of June 15, was down 8.2% from the previous period. Note that it was 47% of the total float, as well as the second highest short interest in at least a year. The days to cover dropped from more than 12 to about eight. In early June, it looked like MannKind had become a tug-o-war stock. Shares ended Wednesday at $5.85, in a 52-week range of $3.46 to $11.48. The stock saw a share price increase of more than 40% in early June, though it gave up much of that gain by the end of the two-week short-interest period.

    Sentiment: Strong Buy

  • I am sure everyone already know this article , I bought few more K, just from the news ...... need more articles weekly.

    Boston drug company Keryx continues to shake off the haters
    Jun 24, 2015, 11:39am EDT
    Don Seiffert
    Boston Business Journal
    , the Baupost Group has increased its “long” shares to 22.4 million shares (22 percent of the company's total) as of June 15. In an interview a month ago, Jason Kolbert, an analyst at Maxim, told me that he’s confident Auryxia will become widely used, because it’s simply a better drug than current phosphate binders. The question, he said, is when.

    Kolbert said at the time he was expecting Keryx to report second quarter Auryxia revenue of $4 million, and third quarter revenue of $8 million. But, he said, if Keryx is able to significantly beat those estimates, it would force the short investors to give up, and clear the way for a fast increase in Keryx’s stock price.

    Sentiment: Strong Buy

  • Reply to

    For the NEWCOMER , IF ANY!

    by pfw2141 Jun 23, 2015 12:12 PM
    pfw2141 pfw2141 Jun 23, 2015 12:55 PM Flag

    Few newcomers are Doctor and Patients, they invest to be in touch with what going on with the progress of MNKD products.
    Few good Friends of mine in Paris, have bought few K because they are curious about the Dreamboat, who could be used for their asthma, word of mouth is a strong way of communication.

    Sentiment: Buy

TGB
0.4694-0.0131(-2.72%)Sep 4 4:00 PMEDT